318 related articles for article (PubMed ID: 12230420)
1. Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease.
Anastos K; Barrón Y; Miotti P; Weiser B; Young M; Hessol N; Greenblatt RM; Cohen M; Augenbraun M; Levine A; Muñoz A;
Arch Intern Med; 2002 Sep; 162(17):1973-80. PubMed ID: 12230420
[TBL] [Abstract][Full Text] [Related]
2. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.
Anastos K; Barrón Y; Cohen MH; Greenblatt RM; Minkoff H; Levine A; Young M; Gange SJ
Ann Intern Med; 2004 Feb; 140(4):256-64. PubMed ID: 14970148
[TBL] [Abstract][Full Text] [Related]
3. The relationship between non-injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use.
Kapadia F; Cook JA; Cohen MH; Sohler N; Kovacs A; Greenblatt RM; Choudhary I; Vlahov D
Addiction; 2005 Jul; 100(7):990-1002. PubMed ID: 15955015
[TBL] [Abstract][Full Text] [Related]
4. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
[TBL] [Abstract][Full Text] [Related]
6. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies.
Chêne G; Sterne JA; May M; Costagliola D; Ledergerber B; Phillips AN; Dabis F; Lundgren J; D'Arminio Monforte A; de Wolf F; Hogg R; Reiss P; Justice A; Leport C; Staszewski S; Gill J; Fatkenheuer G; Egger ME;
Lancet; 2003 Aug; 362(9385):679-86. PubMed ID: 12957089
[TBL] [Abstract][Full Text] [Related]
7. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
Ho C; Lee S; Wong Kh; Cheng L; Lam M
HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
[TBL] [Abstract][Full Text] [Related]
8. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
[TBL] [Abstract][Full Text] [Related]
9. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
[TBL] [Abstract][Full Text] [Related]
10. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).
Jaén A; Esteve A; Miró JM; Tural C; Montoliu A; Ferrer E; Riera M; Segura F; Force L; Sued O; Vilaró J; Garcia I; Masabeu A; Altès J; Coltet B; Podzamczer D; Murillas J; Navarro G; Gatell JM; Casabona J;
J Acquir Immune Defic Syndr; 2008 Feb; 47(2):212-20. PubMed ID: 18297762
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C and progression of HIV disease.
Sulkowski MS; Moore RD; Mehta SH; Chaisson RE; Thomas DL
JAMA; 2002 Jul; 288(2):199-206. PubMed ID: 12095384
[TBL] [Abstract][Full Text] [Related]
12. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
13. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
[TBL] [Abstract][Full Text] [Related]
14. Higher risk of AIDS or death in patients with lower CD4 cell counts after virally suppressive HAART.
Taiwo BO; Li X; Palella F; Jacobson LP; Margolick JB; Detels R; Rinaldo CR; Phair JP
HIV Med; 2009 Nov; 10(10):657-60. PubMed ID: 19601997
[TBL] [Abstract][Full Text] [Related]
15. Mortality and causes of death in HIV-positive patients receiving antiretroviral therapy at Tshepang Clinic in Doctor George Mukhari Hospital.
Mzileni MO; Longo-Mbenza B; Chephe TJ
Pol Arch Med Wewn; 2008 Oct; 118(10):548-54. PubMed ID: 19112815
[TBL] [Abstract][Full Text] [Related]
16. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women.
Ahdieh-Grant L; Li R; Levine AM; Massad LS; Strickler HD; Minkoff H; Moxley M; Palefsky J; Sacks H; Burk RD; Gange SJ
J Natl Cancer Inst; 2004 Jul; 96(14):1070-6. PubMed ID: 15265968
[TBL] [Abstract][Full Text] [Related]
17. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters.
Writing Committee for the CASCADE Collaboration
Arch Intern Med; 2011 Sep; 171(17):1560-9. PubMed ID: 21949165
[TBL] [Abstract][Full Text] [Related]
18. Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy.
Anastos K; Shi Q; French AL; Levine A; Greenblatt RM; Williams C; DeHovitz J; Delapenha R; Hoover DR
J Acquir Immune Defic Syndr; 2004 Apr; 35(4):383-92. PubMed ID: 15097155
[TBL] [Abstract][Full Text] [Related]
19. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
[TBL] [Abstract][Full Text] [Related]
20. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
